High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer

L. A. Holmberg, T. Demirer, S. Rowley, C. D. Buckner, G. Goodman, Richard Maziarz, J. Klarnet, N. Zuckerman, G. Harrer, R. McCloskey, R. Gersh, R. Goldberg, W. Nichols, A. Jacobs, P. Weiden, P. Montgomery, S. Rivkin, F. R. Appelbaum, W. I. Bensinger

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the efficacy of high-dose chemotherapy (HDC) with busulfan, melphalan and thiotepa (BUMELTT) followed by autologous PBSC infusion in treating patients with advanced ovarian cancer. Thirty-one patients, 18 with stage III/IIIc and 13 with stage IV ovarian cancer, were treated with BU (12 mg/kg), MEL (100 mg/m2) and TT (500 mg/m2) and autologous PBSC rescue. Fifteen patients were in clinical complete remission (CR) at treatment; 11 had platinum-sensitive disease. Sixteen patients were not in CR; two had platinum-sensitive disease. The probabilities of overall survival (OS), event-free survival (EFS) and relapse (R) for all patients at 18 months were 0.57, 0.30 and 0.63; for patients in CR, the rates were 0.87, 0.44 and 0.49 and for patients not in CR, 0.38, 0.13 and 0.81. Two patients (6.5%) died of treatment-related causes. Among the 13 patients with platinum-sensitive disease, all are still alive, with seven having relapsed 129-1021 days after PBSC infusion. OS, EFS and R were 1.00, 0.52 and 0.48. Of the 18 patients with platinum-resistant disease, four remain alive (two in remission). Six patients did not respond and eight relapsed from days 104-429. The OS, EFS and R were 0.33, 0.11 and 0.78. We conclude that BUMELTT is well tolerated in patients with advanced ovarian cancer and results are equivalent to other published HDC regimens.

Original languageEnglish (US)
Pages (from-to)651-659
Number of pages9
JournalBone Marrow Transplantation
Volume22
Issue number7
StatePublished - 1998
Externally publishedYes

Fingerprint

Thiotepa
Busulfan
Melphalan
Ovarian Neoplasms
Platinum
Disease-Free Survival
Survival
Peripheral Blood Stem Cells
Drug Therapy

Keywords

  • Busulfan
  • High-dose chemotherapy
  • Melphalan
  • Ovarian cancer
  • PBSC
  • Thiotepa

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. / Holmberg, L. A.; Demirer, T.; Rowley, S.; Buckner, C. D.; Goodman, G.; Maziarz, Richard; Klarnet, J.; Zuckerman, N.; Harrer, G.; McCloskey, R.; Gersh, R.; Goldberg, R.; Nichols, W.; Jacobs, A.; Weiden, P.; Montgomery, P.; Rivkin, S.; Appelbaum, F. R.; Bensinger, W. I.

In: Bone Marrow Transplantation, Vol. 22, No. 7, 1998, p. 651-659.

Research output: Contribution to journalArticle

Holmberg, LA, Demirer, T, Rowley, S, Buckner, CD, Goodman, G, Maziarz, R, Klarnet, J, Zuckerman, N, Harrer, G, McCloskey, R, Gersh, R, Goldberg, R, Nichols, W, Jacobs, A, Weiden, P, Montgomery, P, Rivkin, S, Appelbaum, FR & Bensinger, WI 1998, 'High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer', Bone Marrow Transplantation, vol. 22, no. 7, pp. 651-659.
Holmberg, L. A. ; Demirer, T. ; Rowley, S. ; Buckner, C. D. ; Goodman, G. ; Maziarz, Richard ; Klarnet, J. ; Zuckerman, N. ; Harrer, G. ; McCloskey, R. ; Gersh, R. ; Goldberg, R. ; Nichols, W. ; Jacobs, A. ; Weiden, P. ; Montgomery, P. ; Rivkin, S. ; Appelbaum, F. R. ; Bensinger, W. I. / High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. In: Bone Marrow Transplantation. 1998 ; Vol. 22, No. 7. pp. 651-659.
@article{f115bc74372e40d39f214f9b23fd1d1e,
title = "High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer",
abstract = "The purpose of this study was to evaluate the efficacy of high-dose chemotherapy (HDC) with busulfan, melphalan and thiotepa (BUMELTT) followed by autologous PBSC infusion in treating patients with advanced ovarian cancer. Thirty-one patients, 18 with stage III/IIIc and 13 with stage IV ovarian cancer, were treated with BU (12 mg/kg), MEL (100 mg/m2) and TT (500 mg/m2) and autologous PBSC rescue. Fifteen patients were in clinical complete remission (CR) at treatment; 11 had platinum-sensitive disease. Sixteen patients were not in CR; two had platinum-sensitive disease. The probabilities of overall survival (OS), event-free survival (EFS) and relapse (R) for all patients at 18 months were 0.57, 0.30 and 0.63; for patients in CR, the rates were 0.87, 0.44 and 0.49 and for patients not in CR, 0.38, 0.13 and 0.81. Two patients (6.5{\%}) died of treatment-related causes. Among the 13 patients with platinum-sensitive disease, all are still alive, with seven having relapsed 129-1021 days after PBSC infusion. OS, EFS and R were 1.00, 0.52 and 0.48. Of the 18 patients with platinum-resistant disease, four remain alive (two in remission). Six patients did not respond and eight relapsed from days 104-429. The OS, EFS and R were 0.33, 0.11 and 0.78. We conclude that BUMELTT is well tolerated in patients with advanced ovarian cancer and results are equivalent to other published HDC regimens.",
keywords = "Busulfan, High-dose chemotherapy, Melphalan, Ovarian cancer, PBSC, Thiotepa",
author = "Holmberg, {L. A.} and T. Demirer and S. Rowley and Buckner, {C. D.} and G. Goodman and Richard Maziarz and J. Klarnet and N. Zuckerman and G. Harrer and R. McCloskey and R. Gersh and R. Goldberg and W. Nichols and A. Jacobs and P. Weiden and P. Montgomery and S. Rivkin and Appelbaum, {F. R.} and Bensinger, {W. I.}",
year = "1998",
language = "English (US)",
volume = "22",
pages = "651--659",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer

AU - Holmberg, L. A.

AU - Demirer, T.

AU - Rowley, S.

AU - Buckner, C. D.

AU - Goodman, G.

AU - Maziarz, Richard

AU - Klarnet, J.

AU - Zuckerman, N.

AU - Harrer, G.

AU - McCloskey, R.

AU - Gersh, R.

AU - Goldberg, R.

AU - Nichols, W.

AU - Jacobs, A.

AU - Weiden, P.

AU - Montgomery, P.

AU - Rivkin, S.

AU - Appelbaum, F. R.

AU - Bensinger, W. I.

PY - 1998

Y1 - 1998

N2 - The purpose of this study was to evaluate the efficacy of high-dose chemotherapy (HDC) with busulfan, melphalan and thiotepa (BUMELTT) followed by autologous PBSC infusion in treating patients with advanced ovarian cancer. Thirty-one patients, 18 with stage III/IIIc and 13 with stage IV ovarian cancer, were treated with BU (12 mg/kg), MEL (100 mg/m2) and TT (500 mg/m2) and autologous PBSC rescue. Fifteen patients were in clinical complete remission (CR) at treatment; 11 had platinum-sensitive disease. Sixteen patients were not in CR; two had platinum-sensitive disease. The probabilities of overall survival (OS), event-free survival (EFS) and relapse (R) for all patients at 18 months were 0.57, 0.30 and 0.63; for patients in CR, the rates were 0.87, 0.44 and 0.49 and for patients not in CR, 0.38, 0.13 and 0.81. Two patients (6.5%) died of treatment-related causes. Among the 13 patients with platinum-sensitive disease, all are still alive, with seven having relapsed 129-1021 days after PBSC infusion. OS, EFS and R were 1.00, 0.52 and 0.48. Of the 18 patients with platinum-resistant disease, four remain alive (two in remission). Six patients did not respond and eight relapsed from days 104-429. The OS, EFS and R were 0.33, 0.11 and 0.78. We conclude that BUMELTT is well tolerated in patients with advanced ovarian cancer and results are equivalent to other published HDC regimens.

AB - The purpose of this study was to evaluate the efficacy of high-dose chemotherapy (HDC) with busulfan, melphalan and thiotepa (BUMELTT) followed by autologous PBSC infusion in treating patients with advanced ovarian cancer. Thirty-one patients, 18 with stage III/IIIc and 13 with stage IV ovarian cancer, were treated with BU (12 mg/kg), MEL (100 mg/m2) and TT (500 mg/m2) and autologous PBSC rescue. Fifteen patients were in clinical complete remission (CR) at treatment; 11 had platinum-sensitive disease. Sixteen patients were not in CR; two had platinum-sensitive disease. The probabilities of overall survival (OS), event-free survival (EFS) and relapse (R) for all patients at 18 months were 0.57, 0.30 and 0.63; for patients in CR, the rates were 0.87, 0.44 and 0.49 and for patients not in CR, 0.38, 0.13 and 0.81. Two patients (6.5%) died of treatment-related causes. Among the 13 patients with platinum-sensitive disease, all are still alive, with seven having relapsed 129-1021 days after PBSC infusion. OS, EFS and R were 1.00, 0.52 and 0.48. Of the 18 patients with platinum-resistant disease, four remain alive (two in remission). Six patients did not respond and eight relapsed from days 104-429. The OS, EFS and R were 0.33, 0.11 and 0.78. We conclude that BUMELTT is well tolerated in patients with advanced ovarian cancer and results are equivalent to other published HDC regimens.

KW - Busulfan

KW - High-dose chemotherapy

KW - Melphalan

KW - Ovarian cancer

KW - PBSC

KW - Thiotepa

UR - http://www.scopus.com/inward/record.url?scp=0031766638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031766638&partnerID=8YFLogxK

M3 - Article

C2 - 9818692

AN - SCOPUS:0031766638

VL - 22

SP - 651

EP - 659

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -